NATIONAL BUREAU OF ECONOMIC RESEARCH
NATIONAL BUREAU OF ECONOMIC RESEARCH

Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry

Daron Acemoglu, Joshua Linn

NBER Working Paper No. 10038
Issued in October 2003
NBER Program(s):   HE   IO   PR

This paper investigates the effect of (potential) market size on entry of new drugs and pharmaceutical innovation. Focusing on exogenous changes driven by U.S. demographic trends, we find that a 1 percent increase in the potential market size for a drug category leads to a 4 to 6 percent increase in the number of new drugs in that category. This response comes from both the entry of generic drugs and new non-generic drugs, and is generally robust to controlling for a variety of non-profit factors, pre-existing trends

download in pdf format
   (604 K)

email paper

The NBER Bulletin on Aging and Health provides summaries of publications like this.  You can sign up to receive the NBER Bulletin on Aging and Health by email.

This paper is available as PDF (604 K) or via email.

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.3386/w10038

Published: Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," The Quarterly Journal of Economics, MIT Press, vol. 119(3), pages 1049-1090, August. citation courtesy of

Users who downloaded this paper also downloaded these:
Acemoglu, Cutler, Finkelstein, and Linn w11949 Did Medicare Induce Pharmaceutical Innovation?
Campbell and Hopenhayn w9113 Market Size Matters
Acemoglu w8287 Directed Technical Change
Morton w6190 Entry Decisions in the Generic Pharmaceutical Industry
Berry and Waldfogel w9675 Product Quality and Market Size
 
Publications
Activities
Meetings
NBER Videos
Data
People
About

Support
National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email: info@nber.org

Contact Us